ArticleMedicine2026
Live attenuated varicella vaccines in patients treated with tumor necrosis factor-alpha inhibitors: A clinical trial.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLive vaccines are generally contraindicated in patients treated with biological agents. However, they are often needed in this patient population. This prospective study aimed to evaluate the immunogenicity and safety of the live attenuated varicella vaccine in patients receiving tumor necrosis factor-alpha (TNF-α) inhibitors.
methodsThis single-center, prospective study was conducted at the National Center for Child Health and Development and registered with the Japan Registry of Clinical Trials in accordance with the Japanese Clinical Trials Act. Patients receiving TNF-α inhibitors were enrolled. Those with varicella-specific immunoglobulin G (IgG) levels <4.0 who also met predefined criteria of cellular and humoral immunity were eligible. A single dose of the varicella vaccine was administered, and varicella-specific IgG levels were measured before and after vaccination. Participants were monitored for adverse events for up to 6 months following vaccination.
resultsTen pediatric patients (five with juvenile idiopathic arthritis and 5 with inflammatory bowel disease) were enrolled. Of these, 5 achieved seroconversion (defined as a varicella-specific IgG level of 4.0 or more) after a single vaccination (seroconversion rate: 50%). Three patients received a booster vaccination, and 1 subsequently achieved seroconversion. Adverse events were nonspecific, and none were related to the varicella vaccine.
conclusionThe varicella vaccine may be acceptable in patients receiving TNF-α inhibitors. However, due to the small sample size, neither the efficacy nor safety can be definitively established in this pilot study. A larger-scale study is warranted to further evaluate immunogenicity and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.